Table 1.
Resting membrane potential determinations in vivo (mV)
| Pretreatment | Treatment |
||||
|---|---|---|---|---|---|
| No drug | BTP2 | Gd3+ | GsMTx-4 | Dantrolene | |
| Control | |||||
| WT | −82 ± 1.4 (n=121) | −83 ± 1.1 (n=13) | −82 ± 1.3 (n=13) | −82 ± 1.7 (n=9) | −82 ± 1.2 (n=14) |
| R163C-MHS | −82 ± 1.3 (n=143) | −83 ± 1 (n=13) | −82 ± 1.4 (n=23) | −82 ± 1.7 (n=9) | −82 ± 1.4 (n=11) |
| Halothane | |||||
| WT | −82 ± 1.2 (n=84) | −83 ± 1.2 (n=22) | −82 ± 1.5 (n=26) | −82 ± 1.4 (n=23) | −82 ± 1.5 (n=21) |
| R163C-MHS | −78 ± 1 (n=90)* | −78 ± 1.1 (n=22)* | −77 ± 1.3 (n=25)* | −78 ± 1 (n=23)* | −81 ± 1 (n=21) |
Resting membrane potentials values are expressed as means ± sd; n represents the number of measurements carried out in muscle fibers from 18 WT and 24 R163C-MHS mice.
*
P < 0.05 vs. R163C-MHS without halothane (1-way ANOVA, Kruskal-Wallis test, Dunn's multiple-comparison test).